Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | MC4R | P32245 | 6/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 3/20 | 0.35 |
| ▸ | FAAH | O00519 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL733087 | 1.00 | SCD5 (0.39) | SCD5DRD2DRD3ALDH1A1MAOA | |
| SCHEMBL1971832 | 0.90 | DRD2 (0.39) | DRD2DRD3RORCIDH1FAAH | |
| SCHEMBL751717 | 0.90 | SCD5 (0.38) | SCD5DRD2DRD3ALDH1A1MAOA | |
| SCHEMBL1969732 | 0.90 | DRD2 (0.39) | DRD2DRD3RORCIDH1FAAH | |
| SCHEMBL1920901 | 0.87 | RORC (0.47) | DRD2DRD3MC4RRORCATM | |
| SCHEMBL1971383 | 0.87 | RORC (0.47) | DRD2DRD3MC4RRORCATM | |
| SCHEMBL1971708 | 0.87 | RORC (0.47) | DRD2DRD3MC4RRORCATM | |
| SCHEMBL13493089 | 0.87 | SCD5 (0.37) | SCD5MC4RIDH1FAAH | |
| SCHEMBL12560887 | 0.87 | SCD5 (0.37) | SCD5MC4RIDH1FAAH | |
| SCHEMBL18482300 | 0.87 | SCD5 (0.37) | SCD5MC4RIDH1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1989196-B1 | PIPERIDINOYLPYRROLIDINES AS MELANOCORTIN TYPE 4 RECEPTOR AGONISTS | PFIZER LTD (GB) | 2013-02-13 | — | — | EP | disclosed |
| US-8138188-B2 | Melanocortin type 4 receptor agonist piperidinoylpyrrolidines | PFIZER INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20090036459-A1 | Melanocortin Type 4 Receptor Agonist Piperidinoylpyrrolidines | PFIZER INC | 2009-02-05 | — | — | US | disclosed |
| US-20080269233-A1 | Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds | ANDREWS MARK DAVID | 2008-10-30 | — | — | US | disclosed |
| EP-1912968-A1 | PIPERIDINOYL-PYRROLIDINE AND PIPERIDINOYL-PIPERIDINE COMPOUNDS | Pfizer Limited (GB) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007015162-A1 | PIPERIDINOYL-PYRROLIDINE AND PIPERIDINOYL-PIPERIDINE COMPOUNDS | PFIZER LIMITED (GB) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036459-A1 | Melanocortin Type 4 Receptor Agonist Piperidinoylpyrrolidines | MC4R, MC5R, MC3R | SCD5 2438/4885DRD2 298/4885DRD3 262/4885 |
| US-20080269233-A1 | Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds | GPR4, GPR119, PRLHR | SCD5 3041/4885DRD2 334/4885DRD3 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.